The role of the urologist in adjuvant chemotherapy trials for prostate cancer - 07/09/11
Doi : 10.1016/S0090-4295(99)00454-9
Joseph C Presti, M.D. a, b, ⁎
a Department of Urology, University of California, San Francisco, San Francisco, California,, USA
b UCSF/Mt. Zion Cancer Center, San Francisco, California, USA
*Reprint requests: Joseph C. Presti, Jr., M.D., Urologic Oncology, 5th Floor, UCSF/Mt. Zion Cancer Center, 2356 Sutter Street, San Francisco, CA 94115-1711
Abstract |
The urologist is ideally positioned to identify patients at high risk for relapse after radical prostatectomy. Several models have been proposed to help the urologist identify which patients are at risk and who should be considered for adjuvant therapy after radical prostatectomy. The appropriate initial trial design considered for this group of patients should be a randomized two-arm trial, without androgen deprivation, to assess more quickly the efficacy of selected agents.
Le texte complet de cet article est disponible en PDF.Plan
© 1999
Elsevier Science Inc. Tous droits réservés.
Vol 54 - N° 6S1
P. 47-50 - décembre 1999 Retour au numéro
Article précédent
- Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
- Martin E Gleave, Hideaki Miayake, Jim Goldie, Colleen Nelson, Anthony Tolcher
- Summary: the role of the urologist in chemotherapy of hormone refractory prostate cancer
- E.David Crawford
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?